BioSante Pharma Completes Enrollment in Pivotal LibiGel Trials – Video

Posted by Dr. Michael White, Published on November 2nd, 2012


Video Download: YouTube Video Here



BioSante Pharma Completes Enrollment in Pivotal LibiGel Trials
BioSante Pharmaceuticals (BPAX) announced today that enrollment of subjects in the second of two pivotal Phase III safety and efficacy trials for LibiGel, a testosterone gel being developed to treat female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, has been completed. Enrollment in the first efficacy trial was completed in February. The trials are being conducted under an FDA-approved special protocol assessment (SPA) agreement.From:TradeTheTrendViews:144 0ratingsTime:00:34More inNews Politics

Read the original here:

BioSante Pharma Completes Enrollment in Pivotal LibiGel Trials - Video

Related Post

Contact Us Now


Your Name (*)
Your Email (*)
Your Phone (*)
Select A Program
Select Your US State (*)
Select your age (30+ only)
Confirm over 30 years old (*) Yes
Confirm United States Resident? (*) Yes
(*) - Required
After completing the contact form above, press the submit button. We will send you a confirmation email. Please check your email. For security purposes, please give us a call at 1-800-469-3343 if you don't receive an email.


How useful was this post?

Click on a smiley face to rate it!

Average rating / 5. Vote count:

Word Count: 105

Comments are closed.


symptoms specialist and testosterone in males low signs of

testosterone levels by age
testosterone cypionate half life
normal levels pg ml